In designing CS-6, we had the advantage of knowing that simple benzopyrans such as genistein were thought to be capable of crossing the blood-brain barrier(1) The issue was whether more complex structures such as superbenzopyrans could do so and whether we would be able to meet the 5 key structural requirements for molecules capable of crossing the blood-brain barrier. CS-6 scores nearly full marks on all 5 rules, indicating a very high probability of being able to cross the blood-brain barrier.
(1). Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. Tsai TH. J Chromatogr A. (2005) 1073: 317-22.
CS-6 is highly active against glioma cancer cell lines in vitro.
CS-6 currently is undergoing pre-clinical testing. It is undergoing a series of standard animal tests that it is hoped will allow it to enter human clinical trials in mid-2014.
NRT Price at posting:
21.5¢ Sentiment: Buy Disclosure: Held
